Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Profile

Joseph Saseen

Concepts (455)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
25
2025
430
4.440
 Why?
Hypertension
23
2024
1242
2.860
 Why?
Pharmacists
17
2023
246
2.800
 Why?
Antihypertensive Agents
14
2024
485
2.790
 Why?
Cardiovascular Diseases
20
2025
2003
2.040
 Why?
Atherosclerosis
6
2025
402
2.020
 Why?
Cholesterol, LDL
12
2024
358
1.930
 Why?
Students, Pharmacy
7
2018
96
1.850
 Why?
Hypercholesterolemia
8
2025
102
1.750
 Why?
Educational Measurement
5
2018
260
1.510
 Why?
Hypolipidemic Agents
8
2021
92
1.490
 Why?
Blood Pressure
12
2024
1736
1.430
 Why?
Professional Role
7
2020
157
1.420
 Why?
Education, Pharmacy
7
2018
119
1.410
 Why?
Practice Guidelines as Topic
13
2020
1497
1.270
 Why?
Medication Therapy Management
5
2018
72
1.250
 Why?
Anticholesteremic Agents
7
2021
150
1.210
 Why?
Dyslipidemias
7
2016
177
1.190
 Why?
Lipids
3
2022
625
1.170
 Why?
Ambulatory Care
9
2018
504
1.120
 Why?
Cholesterol
5
2020
412
1.110
 Why?
Calcium Channel Blockers
7
2015
161
1.080
 Why?
Managed Care Programs
4
2014
133
1.060
 Why?
Societies, Pharmaceutical
7
2017
21
0.970
 Why?
Humans
132
2025
129266
0.940
 Why?
Practice Patterns, Physicians'
5
2023
1267
0.940
 Why?
Hydrochlorothiazide
2
2014
9
0.940
 Why?
Chlorthalidone
2
2014
7
0.930
 Why?
Pharmaceutical Services
5
2020
81
0.920
 Why?
Arthritis, Gouty
2
2016
14
0.910
 Why?
Urinary Tract Infections
2
2023
151
0.860
 Why?
Anti-Inflammatory Agents, Non-Steroidal
5
2018
338
0.850
 Why?
Adrenergic beta-Antagonists
4
2014
321
0.840
 Why?
Education, Pharmacy, Graduate
4
2017
17
0.830
 Why?
Pharmacy Residencies
3
2018
11
0.820
 Why?
Retrospective Studies
35
2024
14461
0.800
 Why?
Diabetes Mellitus
4
2023
1000
0.800
 Why?
American Heart Association
4
2020
296
0.800
 Why?
Clinical Competence
4
2018
1016
0.790
 Why?
Blood Glucose
4
2017
2097
0.760
 Why?
Gout
3
2020
33
0.750
 Why?
Dicarboxylic Acids
1
2021
6
0.730
 Why?
Diuretics
4
2014
75
0.730
 Why?
Coronary Artery Disease
3
2021
679
0.730
 Why?
Serotonin 5-HT1 Receptor Agonists
1
2020
4
0.720
 Why?
Evidence-Based Medicine
14
2018
712
0.720
 Why?
Preceptorship
2
2018
65
0.720
 Why?
Angiotensin-Converting Enzyme Inhibitors
5
2011
198
0.710
 Why?
Drug Prescriptions
2
2020
247
0.710
 Why?
Aged
37
2025
22032
0.700
 Why?
Teaching
3
2018
214
0.690
 Why?
Diabetes Mellitus, Type 2
7
2022
2439
0.690
 Why?
Hypoglycemic Agents
4
2014
1219
0.680
 Why?
Primary Health Care
9
2024
1678
0.660
 Why?
Middle Aged
40
2025
31090
0.650
 Why?
Muscular Diseases
2
2015
107
0.650
 Why?
Emergency Service, Hospital
2
2020
1896
0.640
 Why?
Proton Pump Inhibitors
2
2024
100
0.640
 Why?
Migraine Disorders
1
2020
101
0.630
 Why?
Health Benefit Plans, Employee
2
2017
22
0.620
 Why?
Drug Therapy
2
2017
80
0.610
 Why?
Acetaminophen
3
2007
246
0.590
 Why?
Fatty Acids
1
2021
427
0.580
 Why?
Insurance Coverage
2
2011
218
0.570
 Why?
Simvastatin
3
2015
60
0.560
 Why?
Faculty, Pharmacy
1
2017
20
0.540
 Why?
Schools, Pharmacy
1
2017
46
0.540
 Why?
Research
2
2017
416
0.530
 Why?
Aged, 80 and over
15
2025
7055
0.520
 Why?
HIV
1
2017
226
0.510
 Why?
Population Health
1
2017
46
0.510
 Why?
Primary Prevention
3
2024
188
0.500
 Why?
Cardiology
4
2018
261
0.500
 Why?
Female
50
2025
68551
0.500
 Why?
Perception
1
2018
337
0.490
 Why?
Male
45
2025
63512
0.490
 Why?
Monitoring, Physiologic
1
2017
265
0.490
 Why?
Heart Failure
3
2023
2135
0.480
 Why?
Hyperlipidemias
5
2018
126
0.480
 Why?
Antipsychotic Agents
1
2017
195
0.480
 Why?
Anti-Retroviral Agents
1
2017
231
0.480
 Why?
Adult
31
2021
35495
0.480
 Why?
Treatment Outcome
17
2024
10202
0.460
 Why?
Faculty, Medical
1
2017
260
0.460
 Why?
Poverty
2
2008
496
0.450
 Why?
Angiotensin II Type 1 Receptor Blockers
2
2013
36
0.450
 Why?
Gastrointestinal Hemorrhage
2
2024
121
0.440
 Why?
United States
23
2025
13826
0.440
 Why?
Program Evaluation
3
2017
872
0.440
 Why?
Gout Suppressants
2
2020
17
0.440
 Why?
Analgesics, Non-Narcotic
2
2007
119
0.440
 Why?
Aspirin
3
2024
380
0.430
 Why?
Tetrazoles
1
2013
38
0.430
 Why?
Drug Therapy, Combination
12
2020
1040
0.420
 Why?
Self Report
1
2017
795
0.420
 Why?
Ezetimibe
4
2021
25
0.420
 Why?
Curriculum
6
2018
910
0.410
 Why?
Osteoarthritis
2
2006
168
0.410
 Why?
Adrenal Cortex Hormones
2
2016
522
0.410
 Why?
Gemfibrozil
3
2016
11
0.410
 Why?
Analgesics, Opioid
1
2020
909
0.410
 Why?
Anti-Arrhythmia Agents
2
2003
111
0.400
 Why?
Venoms
1
2012
29
0.390
 Why?
Imidazoles
1
2013
234
0.390
 Why?
Colorado
13
2024
4406
0.390
 Why?
Text Messaging
2
2025
149
0.380
 Why?
Health Expenditures
5
2017
179
0.370
 Why?
Electronic Health Records
5
2018
970
0.370
 Why?
Kidney
1
2019
1385
0.370
 Why?
Problem-Based Learning
3
2017
78
0.370
 Why?
Lipoprotein(a)
2
2022
67
0.370
 Why?
Health Resources
1
2012
113
0.360
 Why?
Renal Insufficiency, Chronic
1
2017
566
0.350
 Why?
Medicare Part D
1
2011
24
0.350
 Why?
Risk Factors
17
2024
9745
0.350
 Why?
Risk Assessment
11
2022
3232
0.350
 Why?
Arthritis, Rheumatoid
3
2009
1097
0.330
 Why?
Patient Care Team
5
2024
601
0.330
 Why?
Insurance Claim Review
3
2017
64
0.330
 Why?
Azetidines
2
2008
40
0.320
 Why?
Drug Interactions
4
2022
393
0.310
 Why?
Antirheumatic Agents
2
2009
280
0.300
 Why?
Antibodies, Monoclonal
4
2020
1367
0.300
 Why?
Clinical Trials as Topic
8
2017
1004
0.300
 Why?
Age Factors
5
2017
3140
0.290
 Why?
Community Health Centers
2
2018
57
0.290
 Why?
Cohort Studies
10
2020
5409
0.290
 Why?
Venous Thromboembolism
2
2022
284
0.280
 Why?
Drug Costs
2
2006
100
0.280
 Why?
Consensus
4
2025
615
0.280
 Why?
Societies, Medical
4
2025
744
0.280
 Why?
HIV Infections
2
2023
2719
0.280
 Why?
Platelet Aggregation Inhibitors
2
2024
442
0.270
 Why?
Kidney Failure, Chronic
2
2010
546
0.270
 Why?
Verapamil
2
1997
41
0.270
 Why?
Certification
2
2006
94
0.270
 Why?
Dipeptidyl-Peptidase IV Inhibitors
1
2007
45
0.270
 Why?
Weight Loss
3
2012
732
0.270
 Why?
Peptides
1
2012
923
0.270
 Why?
Family Practice
4
2015
455
0.260
 Why?
Liver Diseases, Alcoholic
1
2007
89
0.260
 Why?
Tablets
1
2006
36
0.260
 Why?
Renal Dialysis
1
2010
423
0.260
 Why?
Randomized Controlled Trials as Topic
7
2007
1365
0.260
 Why?
Cyclooxygenase 2 Inhibitors
1
2006
21
0.260
 Why?
Young Adult
9
2021
12391
0.260
 Why?
Drug Compounding
1
2006
97
0.250
 Why?
Lipoproteins
1
2007
171
0.250
 Why?
Reminder Systems
2
2025
173
0.250
 Why?
Sodium Chloride, Dietary
1
2006
31
0.250
 Why?
Chemical and Drug Induced Liver Injury
2
2007
132
0.250
 Why?
Patient Care
3
2017
108
0.250
 Why?
Insurance, Health
4
2015
265
0.240
 Why?
Benzothiadiazines
1
2005
3
0.240
 Why?
Guideline Adherence
3
2020
526
0.240
 Why?
Sodium Chloride Symporter Inhibitors
1
2005
9
0.240
 Why?
Ambulatory Care Facilities
2
2017
226
0.240
 Why?
Brain Ischemia
1
2008
321
0.240
 Why?
Blood Pressure Determination
3
2018
148
0.240
 Why?
Drug Labeling
3
2015
40
0.230
 Why?
Quality Assurance, Health Care
1
2006
317
0.230
 Why?
Bronchiolitis, Viral
1
2004
11
0.220
 Why?
Glomerular Filtration Rate
2
2019
711
0.220
 Why?
Patient-Centered Care
3
2015
505
0.220
 Why?
Epinephrine
1
2004
141
0.210
 Why?
Life Style
1
2006
459
0.210
 Why?
Off-Label Use
2
2015
51
0.210
 Why?
Incidence
3
2023
2636
0.210
 Why?
Contraceptive Agents
1
2004
65
0.210
 Why?
Progesterone Congeners
1
2003
17
0.210
 Why?
Medroxyprogesterone
1
2003
10
0.210
 Why?
Cardiovascular Agents
1
2025
156
0.210
 Why?
Hormone Replacement Therapy
1
2004
92
0.210
 Why?
Secondary Prevention
3
2024
218
0.210
 Why?
Quality Indicators, Health Care
1
2005
298
0.210
 Why?
Estrogens, Conjugated (USP)
1
2003
46
0.200
 Why?
Faculty
2
2018
137
0.200
 Why?
Tumor Necrosis Factor-alpha
1
2007
1202
0.200
 Why?
C-Reactive Protein
1
2005
400
0.200
 Why?
Heart Conduction System
1
2003
95
0.200
 Why?
Bronchodilator Agents
1
2004
243
0.200
 Why?
Medication Adherence
3
2025
556
0.190
 Why?
Program Development
2
2017
355
0.190
 Why?
Contraception
1
2004
153
0.190
 Why?
Death, Sudden, Cardiac
1
2003
179
0.190
 Why?
Estrogen Replacement Therapy
1
2003
137
0.190
 Why?
Attitude to Health
1
2005
430
0.190
 Why?
Atenolol
2
2014
6
0.180
 Why?
Communicable Diseases
1
2023
147
0.180
 Why?
Antiphospholipid Syndrome
1
2021
37
0.180
 Why?
Vasodilator Agents
1
2003
326
0.180
 Why?
Pre-Exposure Prophylaxis
1
2023
203
0.180
 Why?
Drug Tolerance
1
2021
90
0.180
 Why?
Xanthine Oxidase
2
2020
78
0.170
 Why?
Transition to Adult Care
1
2022
79
0.170
 Why?
Costs and Cost Analysis
3
2014
201
0.170
 Why?
Public Health Administration
1
2021
75
0.170
 Why?
Diabetic Nephropathies
1
2004
284
0.170
 Why?
Dipyrone
1
1999
1
0.170
 Why?
Stroke
1
2008
1070
0.170
 Why?
Methenamine
1
2019
4
0.170
 Why?
Dose-Response Relationship, Drug
4
2014
2011
0.170
 Why?
Adolescent
7
2020
20313
0.170
 Why?
Appetite Stimulants
1
1999
2
0.160
 Why?
Anti-Infective Agents, Urinary
1
2019
13
0.160
 Why?
HIV Wasting Syndrome
1
1999
4
0.160
 Why?
Anabolic Agents
1
1999
12
0.160
 Why?
Diltiazem
2
1996
28
0.160
 Why?
Nifedipine
2
1996
29
0.160
 Why?
Pharmacy Service, Hospital
2
2013
89
0.160
 Why?
Drug and Narcotic Control
1
1999
28
0.160
 Why?
Patient Education as Topic
3
2024
737
0.160
 Why?
Proprotein Convertase 9
1
2019
68
0.150
 Why?
Internship, Nonmedical
3
2011
16
0.150
 Why?
Heart Rate
1
2003
802
0.150
 Why?
Protons
1
2019
80
0.150
 Why?
Atrial Fibrillation
1
2003
376
0.150
 Why?
Guidelines as Topic
2
2019
263
0.150
 Why?
Federal Government
1
2018
27
0.150
 Why?
Training Support
1
2018
28
0.150
 Why?
Health Services
2
2009
99
0.150
 Why?
Thrombosis
1
2021
343
0.150
 Why?
Risk
2
2017
854
0.150
 Why?
Acquired Immunodeficiency Syndrome
1
1999
227
0.140
 Why?
Medically Underserved Area
1
2018
84
0.140
 Why?
Peripheral Arterial Disease
1
2024
457
0.140
 Why?
Quality of Health Care
2
2017
602
0.140
 Why?
Severity of Illness Index
3
2019
2740
0.140
 Why?
Models, Econometric
1
2017
33
0.140
 Why?
Vulnerable Populations
1
2018
156
0.140
 Why?
Anticoagulants
4
2022
636
0.140
 Why?
Anti-HIV Agents
1
2023
754
0.130
 Why?
Warfarin
3
2021
147
0.130
 Why?
Colchicine
1
2016
24
0.130
 Why?
Point-of-Care Systems
1
2018
147
0.130
 Why?
United States Food and Drug Administration
2
2015
204
0.130
 Why?
Protease Inhibitors
1
2017
106
0.130
 Why?
Hyperuricemia
1
2016
44
0.130
 Why?
Alcoholism
1
2003
765
0.130
 Why?
Chronic Disease
3
2013
1716
0.130
 Why?
Comorbidity
4
2016
1544
0.130
 Why?
Amlodipine
1
2015
10
0.120
 Why?
Uric Acid
1
2016
161
0.120
 Why?
Pharmacovigilance
1
2015
21
0.120
 Why?
Education, Medical, Undergraduate
1
2017
175
0.120
 Why?
Surveys and Questionnaires
2
2018
5384
0.120
 Why?
Liver
1
2003
1839
0.110
 Why?
Exercise
1
2006
1925
0.110
 Why?
Systole
1
2014
191
0.110
 Why?
Ethanolamines
1
2014
17
0.110
 Why?
Nebivolol
1
2014
9
0.110
 Why?
Benzopyrans
1
2014
25
0.110
 Why?
Metoprolol
1
2014
39
0.110
 Why?
Risk Reduction Behavior
3
2022
209
0.110
 Why?
Follow-Up Studies
3
2016
4887
0.110
 Why?
Carbazoles
1
2014
84
0.110
 Why?
Losartan
1
2013
14
0.110
 Why?
Valsartan
1
2013
27
0.110
 Why?
Propanolamines
1
2014
97
0.110
 Why?
Drug Substitution
1
2013
51
0.110
 Why?
Medicaid
1
2017
431
0.100
 Why?
Valine
1
2013
81
0.100
 Why?
Biphenyl Compounds
1
2013
60
0.100
 Why?
Antidepressive Agents, Second-Generation
2
2004
43
0.100
 Why?
Fibric Acids
1
2012
3
0.100
 Why?
Socioeconomic Factors
1
2017
1209
0.100
 Why?
Patient Acceptance of Health Care
2
2012
757
0.100
 Why?
Contraindications
1
2012
90
0.100
 Why?
Telemedicine
1
2021
788
0.100
 Why?
Internship and Residency
2
2017
1047
0.100
 Why?
Drug Combinations
2
2016
330
0.100
 Why?
Decision Support Systems, Clinical
1
2015
204
0.100
 Why?
Biomarkers
5
2018
3968
0.100
 Why?
Reproducibility of Results
3
2005
3080
0.100
 Why?
Double-Blind Method
4
2003
1875
0.090
 Why?
Age Distribution
1
2012
372
0.090
 Why?
Vascular Endothelial Growth Factor A
1
2014
530
0.090
 Why?
Annual Reports as Topic
1
2010
3
0.090
 Why?
Professional Staff Committees
1
2010
13
0.090
 Why?
Sex Factors
1
2017
1965
0.090
 Why?
Financing, Personal
1
2011
26
0.090
 Why?
Insurance Benefits
1
2010
11
0.090
 Why?
Insurance, Pharmaceutical Services
1
2010
23
0.090
 Why?
Interpersonal Relations
1
2014
391
0.090
 Why?
Acute Kidney Injury
1
2018
790
0.090
 Why?
Pharmacy
1
2010
31
0.090
 Why?
Creatinine
1
2012
491
0.080
 Why?
Analysis of Variance
1
2012
1288
0.080
 Why?
Drug Utilization Review
2
2006
57
0.080
 Why?
Nutrition Surveys
2
2021
260
0.080
 Why?
Hypoglycemia
1
2014
427
0.080
 Why?
Prescription Drugs
1
2010
112
0.080
 Why?
Hyperlipoproteinemia Type II
2
2019
34
0.080
 Why?
Dipyridamole
1
2008
28
0.080
 Why?
Ezetimibe, Simvastatin Drug Combination
1
2008
1
0.080
 Why?
Fluorobenzenes
1
2008
15
0.070
 Why?
Rosuvastatin Calcium
1
2008
20
0.070
 Why?
Ticlopidine
1
2008
54
0.070
 Why?
Patient Compliance
3
2008
563
0.070
 Why?
Drug Administration Schedule
2
2007
768
0.070
 Why?
Ischemic Attack, Transient
1
2008
60
0.070
 Why?
Abatacept
1
2007
46
0.070
 Why?
Health Knowledge, Attitudes, Practice
1
2016
1276
0.070
 Why?
Proportional Hazards Models
1
2011
1197
0.070
 Why?
Antibodies, Monoclonal, Murine-Derived
1
2007
87
0.070
 Why?
Hemorrhage
2
2022
678
0.070
 Why?
Dipeptidyl Peptidase 4
1
2007
13
0.070
 Why?
Adamantane
1
2007
16
0.070
 Why?
Timolol
1
2007
14
0.070
 Why?
Propranolol
1
2007
50
0.070
 Why?
Contraception, Postcoital
1
2007
7
0.070
 Why?
Accreditation
1
2007
80
0.070
 Why?
Pyrrolidines
1
2007
67
0.070
 Why?
Community Pharmacy Services
1
2007
43
0.070
 Why?
Rituximab
1
2007
164
0.070
 Why?
Levonorgestrel
1
2007
37
0.070
 Why?
Specialty Boards
1
2006
32
0.070
 Why?
Nitriles
1
2007
172
0.060
 Why?
Immunoconjugates
1
2007
103
0.060
 Why?
Anti-Ulcer Agents
1
2006
15
0.060
 Why?
Cost Savings
1
2006
78
0.060
 Why?
Medication Errors
1
2006
95
0.060
 Why?
Safety Management
1
2006
112
0.060
 Why?
Delivery of Health Care
3
2022
892
0.060
 Why?
Cross-Sectional Studies
3
2024
5050
0.060
 Why?
Case Management
1
2005
63
0.060
 Why?
Efficiency, Organizational
1
2005
133
0.060
 Why?
Pharmaceutical Preparations
1
2006
171
0.060
 Why?
Pyrimidines
1
2008
459
0.060
 Why?
Benchmarking
1
2005
176
0.060
 Why?
Sulfonamides
1
2008
495
0.060
 Why?
Nephrology
1
2005
60
0.060
 Why?
Geriatrics
1
2025
80
0.060
 Why?
Professional-Patient Relations
1
2005
138
0.050
 Why?
Child, Preschool
2
2017
10459
0.050
 Why?
Rhabdomyolysis
1
2003
22
0.050
 Why?
Enzyme Inhibitors
1
2007
827
0.050
 Why?
Coronary Disease
2
2003
385
0.050
 Why?
Amiodarone
1
2003
24
0.050
 Why?
Albuterol
1
2004
103
0.050
 Why?
Medicare
1
2009
706
0.050
 Why?
Longitudinal Studies
1
2011
2715
0.050
 Why?
Meta-Analysis as Topic
1
2004
170
0.050
 Why?
Disease Susceptibility
1
2005
333
0.050
 Why?
Antineoplastic Agents
1
2014
2054
0.050
 Why?
Liver Function Tests
1
2003
112
0.050
 Why?
Sodium Potassium Chloride Symporter Inhibitors
1
2022
14
0.050
 Why?
Endpoint Determination
1
2003
76
0.050
 Why?
Nocebo Effect
1
2022
9
0.050
 Why?
Cyclohexanols
1
2002
12
0.050
 Why?
Delivery of Health Care, Integrated
2
2018
248
0.050
 Why?
Vaginal Diseases
1
2002
21
0.050
 Why?
Physician-Patient Relations
1
2006
538
0.050
 Why?
Information Dissemination
1
2004
205
0.050
 Why?
Sodium
1
2022
205
0.050
 Why?
Academic Medical Centers
1
2024
474
0.050
 Why?
Kidney Diseases
1
2005
382
0.050
 Why?
Women's Health
1
2004
364
0.040
 Why?
Acute Disease
1
2004
978
0.040
 Why?
Vitamin K 1
1
2000
3
0.040
 Why?
Postmenopause
1
2003
350
0.040
 Why?
Symptom Flare Up
1
2020
38
0.040
 Why?
Medical Audit
2
2013
74
0.040
 Why?
Health Plan Implementation
1
2021
137
0.040
 Why?
Antifibrinolytic Agents
1
2000
47
0.040
 Why?
Liver Diseases
1
2003
290
0.040
 Why?
Aftercare
1
2022
203
0.040
 Why?
Europe
1
2020
363
0.040
 Why?
Patient Satisfaction
1
2004
632
0.040
 Why?
Predictive Value of Tests
1
2005
1949
0.040
 Why?
Neoplasms
1
2014
2449
0.040
 Why?
Rivaroxaban
1
2021
252
0.040
 Why?
Administration, Oral
1
2021
785
0.040
 Why?
Drug Hypersensitivity
1
2000
81
0.040
 Why?
Ibuprofen
1
1999
81
0.040
 Why?
Kidney Function Tests
1
2019
152
0.040
 Why?
Societies, Scientific
1
2019
45
0.040
 Why?
Blood Coagulation
1
2000
238
0.040
 Why?
Child
2
2017
20785
0.040
 Why?
Software
1
2023
606
0.040
 Why?
Student Health Services
1
2018
15
0.040
 Why?
Antiretroviral Therapy, Highly Active
1
1999
267
0.040
 Why?
Self Care
1
2000
365
0.040
 Why?
United States Department of Veterans Affairs
1
2022
623
0.040
 Why?
Hospitals
1
2022
630
0.030
 Why?
Glucose
1
2022
1001
0.030
 Why?
Homozygote
1
2017
193
0.030
 Why?
Felodipine
1
1996
4
0.030
 Why?
Receptors, Drug
1
1996
13
0.030
 Why?
Public Health
1
2021
484
0.030
 Why?
Cost-Benefit Analysis
1
2019
569
0.030
 Why?
Polypharmacy
1
2016
84
0.030
 Why?
Patient Discharge
1
2022
835
0.030
 Why?
Calcium Channels
1
1996
164
0.030
 Why?
Internet
1
1999
615
0.030
 Why?
Cross-Over Studies
1
1997
521
0.030
 Why?
Communication
2
2014
836
0.030
 Why?
Myocardial Ischemia
1
1996
258
0.030
 Why?
Data Interpretation, Statistical
1
1996
336
0.030
 Why?
Regression Analysis
2
2009
991
0.030
 Why?
Antibodies, Monoclonal, Humanized
1
2019
758
0.030
 Why?
Clinical Decision-Making
1
2016
301
0.030
 Why?
Pain
1
1999
786
0.030
 Why?
Infant
2
2004
8975
0.030
 Why?
Pandemics
1
2021
1481
0.030
 Why?
Comprehension
1
2014
164
0.020
 Why?
Hemodynamics
1
1997
1090
0.020
 Why?
Adrenergic Antagonists
1
2011
8
0.020
 Why?
Renin
1
2011
32
0.020
 Why?
Educational Status
1
2014
469
0.020
 Why?
Phytotherapy
1
2011
79
0.020
 Why?
Prospective Studies
3
2015
7123
0.020
 Why?
Health Planning Guidelines
1
2010
25
0.020
 Why?
Drug Utilization
1
2011
171
0.020
 Why?
Breast Neoplasms
1
2003
2140
0.020
 Why?
Poisson Distribution
1
2010
73
0.020
 Why?
Likelihood Functions
1
2010
137
0.020
 Why?
Anti-Bacterial Agents
1
2000
1708
0.020
 Why?
Models, Organizational
1
2011
146
0.020
 Why?
Pilot Projects
1
2015
1584
0.020
 Why?
Preferred Provider Organizations
1
2009
4
0.020
 Why?
Transportation
1
2009
50
0.020
 Why?
Case-Control Studies
1
2016
3377
0.020
 Why?
Private Sector
1
2009
50
0.020
 Why?
Phenotype
1
2017
3074
0.020
 Why?
Infliximab
1
2009
100
0.020
 Why?
Interprofessional Relations
1
2011
275
0.020
 Why?
North America
1
2009
291
0.020
 Why?
Cooperative Behavior
1
2011
433
0.020
 Why?
Quality of Life
1
2019
2687
0.020
 Why?
Multivariate Analysis
1
2010
1497
0.020
 Why?
Organizational Policy
1
2006
79
0.020
 Why?
Health Care Costs
1
2009
367
0.020
 Why?
Professional Practice
1
2006
62
0.020
 Why?
Time Factors
1
1996
6543
0.020
 Why?
Role
1
2005
31
0.020
 Why?
Logistic Models
1
2010
1985
0.020
 Why?
Expert Testimony
1
2005
36
0.010
 Why?
Bone Diseases, Metabolic
1
2005
57
0.010
 Why?
Interdisciplinary Communication
1
2005
184
0.010
 Why?
Models, Economic
1
2004
53
0.010
 Why?
Review Literature as Topic
1
2004
66
0.010
 Why?
Diabetes Complications
1
2005
224
0.010
 Why?
Probability
1
2004
305
0.010
 Why?
Venlafaxine Hydrochloride
1
2002
14
0.010
 Why?
Menstruation
1
2002
44
0.010
 Why?
International Normalized Ratio
1
2000
46
0.010
 Why?
Health Maintenance Organizations
1
2000
97
0.010
 Why?
beta-Lactams
1
2000
28
0.010
 Why?
Medical Records
1
2000
170
0.010
 Why?
Hospitalization
1
2009
2052
0.010
 Why?
Sensitivity and Specificity
1
2004
1839
0.010
 Why?
Depressive Disorder
1
2002
366
0.010
 Why?
Prevalence
1
2005
2553
0.010
 Why?
Depression
1
2004
1306
0.010
 Why?
Saseen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (455) concept(s)
_
Co-Authors Expand Description
See all (50) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)